Antares Pharma, Inc. (ATRS)

[scubastevo80]

I think some of us may be expecting a typical biotech catalyst run to the upside, but we have to realize ATRS isn't your typical biotech. There's no blockbuster drug catalyst in the immediate pipeline, e.g. AMRN's run up before FDA approval.

ATRS is an early stage device manufacturer that has a promising pipeline, coupled with strong management and great partnerships. Personally, I was ecstatic to hear there could be 40 more products introduced in their injectors. I'm also willing to wait for management's game plan to play out through 2017.

Given the diversity of the pipeline and robust plan management has set forth, I think we have a low risk winner here. For every $100M in revenue, we add $5 to the stock by my calculations. At present, the market prices ATRS at doing roughly $70M in revenue, which is well under my most conservative model in 2015. I'm happy to wait will ATRS executes its plan. Have a great weekend all.